文献速递淋巴瘤

靶向CD6的抗体药物偶联物作为T细胞淋巴瘤新型治疗药物

CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma.
PubMed 文献 · Leukemia · 2023-08-12

研究确定CD6在几乎所有受检T细胞淋巴瘤(TCL)患者标本中高表达,并将MMAE偶联至高亲和抗人CD6单克隆抗体制备CD6-ADC。CD6-ADC在体外以时间和浓度依赖方式强效选择性杀伤TCL细胞,在临床前小鼠模型中预防肿瘤发生并显著缩小已建立肿瘤。

要点

  • CD6在几乎所有受检TCL患者标本中高表达,提示其可作为新的治疗靶点。
  • CD6-ADC在体外以时间和浓度依赖方式强效选择性杀伤TCL细胞,对照无效。
  • CD6-ADC或其人源化版本在临床前小鼠模型中显著缩小已建立的肿瘤。

核心结论

  • CD6是TCL的新型治疗靶点,为CD6-ADC作为TCL患者有前景疗法的进一步开发提供有力依据。

研究设计与样本

  • 研究检测TCL患者标本中CD6的表达,并将MMAE偶联至抗人CD6单克隆抗体制备CD6-ADC。
  • 在体外及临床前TCL小鼠模型中比较CD6-ADC与未偶联抗CD6单抗及非结合对照ADC的效果。

主要发现

  • CD6在几乎所有受检TCL患者标本中高表达。
  • CD6-ADC在体外以时间和浓度依赖方式强效选择性杀伤TCL细胞,而未偶联抗CD6单抗和非结合对照ADC无此作用。
  • CD6-ADC在体内临床前TCL模型中预防肿瘤发生。
  • 全身或局部给予CD6-ADC或其人源化版本而非对照,显著缩小临床前小鼠模型中已建立的肿瘤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an established T cell marker, was expressed at high levels on almost all examined TCL patient specimens, suggesting that CD6 could be a new therapeutic target for this life-threatening blood cancer. We prepared a CD6-targeted antibody-drug conjugate (CD6-ADC) by conjugating monomethyl auristatin E (MMAE), an FDA-approved mitotic toxin, to a high-affinity anti-human CD6 monoclonal antibody (mAb). In contrast to both the unconjugated anti-CD6 mAb, and the non-binding control ADC, CD6-ADC potently and selectively killed TCL cells in vitro in both time- and concentration-dependent manners. It also prevented the development of tumors in vivo in a preclinical model of TCL. More importantly, systemic or local administration of the CD6-ADC or its humanized version, but not the controls, significantly shrank established tumors in the preclinical mouse model of TCL. These results suggest that CD6 is a novel therapeutic target in TCLs and provide a strong rationale for the further development of CD6-ADC as a promising therapy for patients with these potentially fatal lymphoid neoplasms.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Parameswaran N, Luo L, Zhang L, et al. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma. Leukemia. 2023. PMID: 37573404. doi:10.1038/s41375-023-01997-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。